| Revenue growth | 11.6% YoY consolidated; 7% YoY standalone. |
|---|---|
| Margins | Consolidated EBITDA margin 14.5% vs 16.0% YoY; Standalone 18.4% vs 21.6% YoY. |
| Demand visibility | Strong, driven by surgery volumes and international patient growth (42% in international). |
| Management confidence | High; emphasizing global leadership in joint replacement. |
Growth
Consolidated revenue grew 11.6% YoY; EBITDA grew 0.9% to ₹490 mn. Standalone revenue grew 7.0% YoY to ₹2,591 mn.
Outlook
Targeting 40% additional bed capacity for organic growth; expansion plan focused on Mumbai hospitals; doubling ROCE via operational leverage.
Risks
EBITDA margins compressed YoY from 16.0% to 14.5% consolidated and 21.6% to 18.4% standalone.
Last quarter's promises, checked
Delivered
- Guided MedTech EBITDA turnaround → delivered ₹3.7 cr (= BEAT)
- Targeted new tax regime benefit → delivered 25% vs 35% rate (= BEAT)
- Guided International patient recovery → delivered 42% growth (= BEAT)
Partly delivered
- Targeted 15% sustainable CAGR → delivered 11.6% revenue growth (= PARTIAL)
- Guided occupancy north of 50% → delivered 48% (50% excl. Gurugram) (= PARTIAL)
Missed
- Guided gross margin maintenance → delivered 85% vs 90% (= MISS)
- Targeted consolidated EBITDA growth → delivered 0.9% vs 43.1% prev (= MISS)
- Guided ARPOB growth → delivered -2.1% YoY (= MISS)
Investor Presentation filed with NSE, NSE: SHALBY. Summary written with AI assistance from the document.
Shalby Ltd: key numbers
- Share price
- ₹134.62
- Market cap
- ₹1,454 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 37.0×Sector 53.1×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Ltd
All →Shalby Management Change
Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.
Shalby Annual General Meeting
Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.
Shalby Other Announcement
Shalby Limited has issued a letter to shareholders providing the web-link for the Annual Report for FY 2025-26. The 22nd Annual General Meeting is scheduled for September 10, 2026.
Shalby Business Update
Shalby Limited filed its Business Responsibility & Sustainability Report (BRSR) for FY 2025-26 as mandated by SEBI LODR regulations.
Shalby Annual General Meeting
Shalby Ltd announced its 22nd Annual General Meeting scheduled for September 10, 2026, and filed its Annual Report for FY 2025-26.
Shalby Earnings Call Transcript: Key Takeaways
Shalby reported a modest 11.6% revenue growth with its MetLife business reaching EBITDA break-even, but hospital margins remain under pressure due to new doctor recruitments.
- Call
- Guides 20% growth